In pharma and MedTech, market research success hinges on answering questions that traditional surveys and clinical trial data simply can’t address. Where are physicians actually prescribing your competitor’s biosimilar? Which patient populations are switching between treatments after three months? What’s driving the 47% variance in device utilization between hospitals in the same region?
Aggregated insurance claims data provides the real-world evidence needed to answer these questions with precision. For commercial teams evaluating market opportunities, HEOR leaders preparing payer submissions, and data scientists building predictive models, connecting with the right claims data providers has become the foundation of strategic decision-making in pharmaceutical market research.
What makes claims data particularly valuable isn’t just its scale—though covering hundreds of millions of patient lives certainly helps. It’s the longitudinal nature of the data, the administrative detail captured for reimbursement, and the ability to map actual patient journeys across providers, treatments, and outcomes. When you’re sizing a market for a diabetes drug, you don’t just need prevalence estimates. You need to understand treatment sequences, switching patterns, adherence rates, and which specialists are managing these patients.
The Foundation: What Claims Data Actually Reveals
Healthcare claims data represents the administrative record of patient interactions with the healthcare system, captured primarily for billing and reimbursement purposes. But this administrative necessity creates something valuable for market research: a comprehensive, standardized record of diagnoses (ICD-10 codes), procedures (CPT codes), prescriptions (ATC codes), and healthcare utilization across millions of lives.
Here’s what distinguishes claims data from other real-world data sources. First, the scale is enormous. Major aggregators like IQVIA PharMetrics® Plus cover over 318 million longitudinal patient records. Komodo Health’s Healthcare Map® processes data representing 330+ million Americans. This isn’t a convenience sample or a regional pilot—it’s population-level intelligence.
Second, claims data is inherently longitudinal. A patient’s journey can be tracked over time, revealing patterns that cross-sectional surveys miss—the progression from first-line to second-line therapy, the gap between diagnosis and treatment initiation, the complications that drive readmissions.
Third, the data structure is standardized. Whether you’re analyzing pharmacy claims from a commercial insurer or medical claims from national health systems, the coding systems (ICD-10, CPT, HCPCS, ATC) provide a common language. This standardization enables comparative analysis across payers, geographies, and time periods that would be impossible with unstructured clinical notes or fragmented registry data.
Now, claims data comes in two primary forms that serve different analytical needs. Open claims provide larger, more current datasets—essential when you’re tracking a newly launched therapy or monitoring competitive dynamics in real-time. The trade-off? These claims haven’t been fully adjudicated yet, so there’s potential for revisions as the billing process completes.
Closed claims offer complete, adjudicated records with finalized reimbursement amounts, making them ideal for health economics research, accurate cost analyses, and long-term trend studies. The FDA’s July 2024 final guidance on real-world evidence explicitly addresses both types, noting that sponsors should carefully evaluate data source selection to ensure it appropriately captures study populations, exposures, and outcomes of interest.
Patient Journey Analytics: Following the Treatment Path
Patient journey analytics represents one of the highest-value applications of claims data in pharmaceutical market research. Traditional market sizing might tell you there are 2.3 million diabetes patients in your target region. Patient journey analysis tells you which 380,000 of those patients are currently on first-line metformin, likely to progress to combination therapy within 18 months, and which 12% will switch to insulin after experiencing persistent A1C levels above target despite two oral agents.
The clinical and commercial intelligence embedded in these journey patterns is substantial. Consider a biosimilar manufacturer preparing to launch an infliximab alternative for inflammatory bowel disease. Claims data reveals not just the total addressable market, but the actual treatment sequencing: What percentage of patients start with oral 5-ASAs? How long until they escalate to immunomodulators? Which specialists manage the transition to biologics? What’s the real-world failure rate on first-line biologics that creates switching opportunities?
Real-world evidence from claims provides longitudinal views of patient experiences, helping companies understand disease prevalence, treatment efficacy, and access barriers in real-world settings beyond controlled clinical trials. This is precisely what health technology assessments and payer negotiations demand—evidence of how therapies perform across heterogeneous patient populations in routine clinical practice.
For MedTech companies, patient journey analysis takes on additional dimensions. When you’re launching an advanced wound care device, claims data can map the entire care pathway from initial diagnosis through treatment escalation. Which patients receive standard dressings? At what point do providers escalate to negative pressure wound therapy? What drives the decision to move from home care to inpatient treatment? Understanding these decision points and the providers making them is critical for commercial strategy.
The technical capability to execute this analysis has evolved dramatically. Providers like Komodo Health use AI-enabled platforms to process billions of claims and construct real-time patient journey maps. Their analytics can identify when patients deviate from standard care pathways, flag gaps in treatment that represent commercial opportunities, and even predict which patients are at high risk for therapy discontinuation.
But here’s where many pharma teams struggle: the data exists, the platforms can process it, but translating journey patterns into actionable commercial strategy requires domain expertise. You need professionals who understand both the clinical progression of disease and the regulatory requirements for evidence generation. Someone who can look at a switching pattern and immediately recognize whether it represents clinical failure, formulary restriction, or patient cost burden.
Competitive Intelligence That Actually Drives Strategy
Competitive intelligence from claims data goes far beyond market share tracking. While knowing that your rheumatoid arthritis biologic holds 23% market share is useful, understanding where you’re losing ground, which patients are switching away, and why timing patterns suggest formulary changes versus clinical decisions—that’s strategically valuable intelligence.
Claims data enables several layers of competitive analysis that traditional market research can’t match. At the provider level, you can identify prescribing patterns across specialties, geographies, and practice settings. Which rheumatologists in major metropolitan areas have the highest volume of biologic-naive patients? Who’s prescribing your competitor’s recently launched JAK inhibitor at twice the regional average? This isn’t just intellectual curiosity—it directly informs territory planning and HCP targeting for your field teams.
The geographic dimension reveals market dynamics that aggregate share numbers mask. A national market share of 23% might hide the fact that you dominate Western Europe (41% share) but have minimal presence in Nordic markets (11% share). Claims data disaggregated by region, country, or even hospital system exposes these variations and the factors driving them—payer coverage, academic center formularies, regional practice patterns.
Treatment sequence analysis provides another competitive lens. Are patients switching from your product to competitors after first-line failure, or are they receiving competitor products as first-line therapy? The commercial implications are profoundly different. First-line displacement suggests you’re losing new starts—a marketing and access problem. Post-failure switching might indicate clinical performance issues or it might simply reflect the natural disease progression as physicians cycle through available therapies.
For MedTech manufacturers, competitive intelligence takes on operational specificity. Claims data can reveal procedure volumes by facility, device utilization patterns, and even indirect evidence of technology adoption through procedure code patterns. When analyzing the cardiac electrophysiology market, claims data shows which hospitals perform high volumes of ablation procedures, which physicians drive those volumes, and how reauthorization patterns suggest patient outcomes and provider confidence in devices.
Here’s what separates sophisticated competitive intelligence from basic market share monitoring: the integration of multiple data dimensions. Combining claims data with lab results exposes referral patterns, reauthorization requirements, and out-of-pocket costs, providing a comprehensive view of the access landscape. This multi-dimensional view reveals why share is shifting—not just that it’s shifting.
The challenge many teams face isn’t accessing competitive intelligence, but processing it fast enough to act. Markets move quickly. A competitor launches, formulary positions change, new clinical data influences prescribing patterns. The value of competitive intelligence degrades rapidly if your analysis cycle takes three months. This is why leading pharma companies are investing in real-time analytics platforms that can process claims data, identify meaningful patterns, and surface insights within days rather than quarters.
Market Sizing and Commercial Planning with Precision
Market sizing has traditionally relied on epidemiological models, physician surveys, and a concerning amount of extrapolation from limited data points. Claims data provides a fundamentally different approach: direct measurement of procedure volumes, prescription patterns, and patient populations using administrative records that capture actual healthcare utilization.
For pharmaceutical companies preparing new product planning (NPP) and launch forecasts, this precision matters enormously. Consider the difference between these approaches to sizing the European market for a novel heart failure therapy:
Traditional approach: Start with prevalence estimates (15 million Continental European adults with heart failure), apply treatment rate assumptions from literature (68% receiving guideline-directed medical therapy), layer on market research about specialist engagement, and project uptake curves based on analogous launches. The final forecast carries compounding uncertainty at each step.
Claims-based approach: Query aggregated claims databases for patients with heart failure diagnoses (ICD-10 I50.*), stratify by severity class using diagnosis codes and procedure patterns, identify current medication regimens through pharmacy claims, segment by ejection fraction using procedure codes and diagnostic testing patterns, and measure actual treatment pathways. The result isn’t a modeled estimate—it’s a direct measurement of how many patients currently receive specific therapies, which physicians manage them, and where treatment gaps exist.
MedTech companies can leverage procedure volume analysis with particular precision. When sizing the market for a next-generation hip replacement system, claims data provides exact counts of primary total hip arthroplasty procedures by facility, surgeon volume tiers, and patient demographics. No assumptions about procedure rates or market penetration—just direct measurement of annual procedures from administrative records.
Geographic granularity represents another critical advantage for commercial planning. Pan-European market size is useful for executive summaries, but territory planning and resource allocation require regional precision. Claims data can show that orthopedic device utilization in Southern European markets is 34% higher than the continental average, while Nordic regions show distinctive patterns in revision procedures. This kind of geographic intelligence directly informs where to deploy sales resources, which markets to prioritize for launch sequencing, and where competitive vulnerabilities exist.
The integration of claims data with other real-world evidence sources creates even more powerful market intelligence. Linking claims to electronic health records can add clinical detail—lab values, vital signs, imaging results—that administrative codes don’t capture. Connecting to specialty pharmacy data reveals adherence patterns and discontinuation rates. Incorporating patient-reported outcomes shows how administrative patterns correlate with quality of life measures.
Real-World Evidence Generation for Regulatory and Payer Submissions
The regulatory landscape around real-world evidence has shifted dramatically, creating both opportunity and complexity for pharma and MedTech companies using claims data. The FDA’s commitment to expanding RWE use in decision-making is clear—since 2016, 35 drug and biologic applications have included RWE, while over 250 medical device premarket authorizations have incorporated real-world data.
What changed in 2024? Two major developments. First, the FDA eliminated a significant barrier by stating it will accept RWE without requiring that identifiable individual patient data from real-world sources always be submitted in marketing applications. This opens the door to using large-scale aggregated claims databases—exactly the type of data sources that contain millions of de-identified patient records.
Second, the FDA finalized its guidance on assessing electronic health records and medical claims data for regulatory decision-making. This guidance discusses critical topics including selection of data sources that appropriately address study questions, development and validation of definitions for study design elements, and data traceability during accrual and curation.
For HEOR teams and market access leaders, this regulatory evolution means claims data can now support effectiveness and safety submissions in ways that weren’t possible five years ago. But—and this is critical—the FDA’s standards for data quality, traceability, and validation are rigorous. You can’t simply pull claims data, run descriptive statistics, and submit it as evidence. The methodology must be transparent, the data sources must be appropriate for your specific study question, and every analytical decision must be documented and justified.
Payer submissions require different but equally stringent evidence. When preparing for P&T committee reviews or health technology assessments across European markets, claims-based analyses must demonstrate comparative effectiveness in real-world populations, cost-effectiveness using actual utilization and outcomes data, and budget impact based on realistic uptake assumptions. Generic literature reviews don’t cut it anymore—payers want to see evidence from patient populations that match their covered lives.
Real-world evidence provides the clinical evidence regarding usage and potential benefits or risks of medical products derived from analysis of real-world data, making it essential for value propositions that resonate with both regulators and payers. The challenge is executing these analyses with sufficient methodological rigor that they withstand expert scrutiny.
Here’s where many companies struggle: building internal capabilities for regulatory-grade RWE generation. It’s not enough to license claims data from IQVIA or Optum. You need epidemiologists who understand outcome ascertainment from administrative codes, biostatisticians familiar with propensity score matching and inverse probability weighting, and regulatory affairs professionals who know what the FDA expects in RWE submissions. That’s a significant capability investment.
The Data Quality Challenge: What Claims Data Can and Cannot Tell You
Claims data is powerful, but it’s not perfect. The limitations matter, and acknowledging them is essential for generating credible insights and avoiding costly analytical mistakes.
The fundamental constraint is this: claims data is collected for billing, not for research. That means the information captured reflects what’s needed for reimbursement, which doesn’t always align with what you need for clinical or commercial analysis. Diagnosis codes indicate conditions relevant to the encounter, but they don’t necessarily capture disease severity, biomarker status, or patient-reported symptoms. You can see that a patient received a CT scan (procedure code), but you can’t see what the scan showed unless that finding drove a new diagnosis code.
Data completeness issues manifest in several ways. Patients switching insurance carriers create fragmented longitudinal histories—you lose visibility when they change plans. Lab results appear inconsistently depending on whether they were ordered by the physician or performed at a reference laboratory. Over-the-counter medications and cash-pay prescriptions don’t generate claims, creating blind spots in medication histories.
Coding accuracy represents another substantial concern. ICD-10 codes can be miscoded, upcoded for reimbursement optimization, or simply used inconsistently across providers. The transition from ICD-9 to ICD-10 created temporal discontinuities that complicate trend analyses. Procedure codes provide standardization, but the specificity varies—some procedures have granular codes while others are grouped broadly.
These limitations aren’t fatal to claims-based research, but they require analytical sophistication to address. The FDA recommends that studies using claims data characterize data according to completeness, conformance and plausibility of data values, document quality assurance plans, and outline procedures for ensuring data integrity. Leading research organizations address these challenges through several approaches:
Data linkage connects claims to other sources—EHRs for clinical detail, specialty pharmacy data for medication adherence, lab data for biomarkers. This multi-source approach fills gaps that any single data type leaves.
Validation studies compare claims-based algorithms against gold-standard clinical data to establish positive predictive values and sensitivity for outcome definitions. When you’re defining “treatment failure” using claims patterns, validation confirms your algorithm actually identifies what you think it does.
Sensitivity analyses test how analytical decisions affect conclusions. If changing your look-back period from 6 to 12 months dramatically shifts your results, that’s important to understand and disclose.
Expert clinical review ensures that analytical choices align with clinical reality. Data scientists understand regression models; clinicians understand disease progression. Both perspectives are necessary.
The Bias Question: Representativeness and Generalizability
Who’s actually represented in claims databases? This isn’t an abstract methodological concern—it directly affects whether your findings generalize to your target population.
Most commercial claims databases skew toward employed populations under age 65 with employer-sponsored insurance. National health system claims databases capture broader populations well. Social insurance claims represent specific coverage groups. But uninsured patients, cash-pay services, and populations with alternative coverage arrangements may be underrepresented or absent entirely.
Geographic representation varies by data provider. Some databases have strong coverage in certain regions but thin coverage in others. Provider participation isn’t universal—some health systems, integrated delivery networks, or academic medical centers may be overrepresented or underrepresented depending on data partnerships.
These representativeness issues create several risks. You might overestimate market size if your data source underrepresents elderly populations for a therapy primarily used in geriatric patients. You might misunderstand regional variations if your database has strong Central European coverage but limited Nordic data. Competitive intelligence might be skewed if academic medical centers (early adopters of novel therapies) are oversampled.
Sophisticated analyses account for these biases through weighting, stratification, and sensitivity analyses that test conclusions across different population segments. But you can’t adjust for what you don’t measure. If your database simply doesn’t include certain patient types, no analytical technique recovers that missing information.
Integration with Advanced Analytics and AI
The volume and complexity of claims data increasingly requires advanced analytics and artificial intelligence to extract value efficiently. Traditional query-and-report approaches can answer specific questions, but they don’t scale to the pattern recognition and predictive modeling that modern pharmaceutical commercial strategy demands.
Machine learning applications in claims analytics have proliferated. Predictive models can forecast which patients are at high risk for therapy discontinuation, enabling proactive patient support programs. Clustering algorithms can segment patient populations into clinically and commercially meaningful subgroups that standard demographic stratification misses. Natural language processing can extract information from unstructured claims notes and connect it to structured code data.
The commercial applications are tangible. A pharmaceutical manufacturer might use machine learning to predict which physicians are likely to prescribe a newly launched therapy based on their historical prescribing patterns, patient mix, and practice characteristics. A MedTech company could develop early warning systems that flag when device utilization patterns deviate from expected norms, potentially indicating clinical issues or competitive incursion.
The FDA’s July 2024 guidance includes discussion of artificial intelligence technologies in the context of data curation and analysis, acknowledging that AI is becoming integral to processing real-world data at scale. But the guidance also emphasizes that AI-enabled analyses must still meet fundamental standards for transparency, validation, and reproducibility.
The challenge with AI in claims analytics isn’t the technology—it’s the expertise required to apply it appropriately. Machine learning models can identify patterns, but domain experts must evaluate whether those patterns are clinically meaningful or just statistical artifacts. Algorithms can predict outcomes, but clinicians must validate that the predictions make medical sense. The most successful implementations combine data science capabilities with deep pharmaceutical industry expertise.
Privacy, Compliance, and the GDPR Framework
Using claims data for market research requires strict compliance with data protection regulations, which protect patient privacy while enabling legitimate uses of de-identified health information. For datasets covering European populations, GDPR compliance is essential and non-negotiable.
The General Data Protection Regulation (GDPR) establishes rigorous standards for processing health data, classified as a special category requiring heightened protection. While GDPR enforcement actions have intensified across multiple sectors, the fundamental principles remain clear: health data must be properly anonymized or pseudonymized, processing must have a lawful basis, and data subjects’ rights must be respected.
For pharmaceutical and MedTech companies using aggregated claims data, several compliance requirements are critical. First, data must be properly de-identified or anonymized according to GDPR standards—removing or transforming information such that individuals cannot be re-identified. Most commercial claims databases undergo this anonymization before being licensed for research, but companies should verify the process used and maintain documentation.
Second, Data Processing Agreements must be in place between data controllers (health plans or systems providing the claims data) and data processors (data aggregators, analytics vendors). These agreements specify how health information can be used, what safeguards must be maintained, and liability arrangements if breaches occur.
Third, data use must align with permitted purposes under applicable regulations. Market research, competitive intelligence, and commercial analytics are generally permissible uses of properly anonymized data. But companies should document the business purpose and ensure that analyses don’t attempt to re-identify individuals, even inadvertently.
Fourth, technical safeguards must protect data at rest and in transit. This includes encryption, access controls, audit logs, and secure disposal procedures when data is no longer needed. Many pharmaceutical companies maintain segregated data environments specifically for real-world data analysis, with enhanced security controls beyond standard corporate networks.
For companies working with U.S. data, HIPAA compliance adds specific requirements around de-identification, Business Associate Agreements, and permitted uses. Companies operating in both U.S. and European markets need expertise in both regulatory frameworks and should implement controls that meet the stricter standard where regulations differ.
Recent developments in data privacy enforcement underscore the importance of robust compliance programs. Organizations must demonstrate not just technical compliance but also accountability—documenting data protection impact assessments, maintaining records of processing activities, and implementing privacy by design principles.
Navigating the Data Landscape: What to Look For
The market for claims data and analytics services has matured significantly, with various providers offering different combinations of data assets, analytical platforms, and consulting services. Choosing the right partner depends on your specific use cases, internal capabilities, and strategic priorities—and navigating this landscape requires expertise.
Understanding what’s available in the market helps frame your requirements, but the real challenge lies in matching your specific needs with the right capabilities. Coverage breadth varies dramatically across providers. Some maintain longitudinal records covering hundreds of millions of patient lives with strong representation across multiple regions. Others focus on specific geographies or therapeutic areas with deeper clinical detail.
Data recency represents another critical dimension. Some sources provide near real-time open claims updated within days of encounters—essential for competitive intelligence and launch monitoring. Others specialize in fully adjudicated closed claims with complete cost data—better suited for health economics research and long-term outcome studies.
When evaluating your data needs, consider these factors beyond just coverage numbers:
Analytical capabilities: Do you need raw data for your own analysis, or pre-built analytics tools and dashboards? Some providers offer self-service query environments; others provide full-service analytics with dedicated teams. Your internal data science maturity should guide this decision.
Integration and interoperability: Can the claims data connect to your other data assets—CRM systems, sales force data, market research? API availability and data format compatibility matter for seamless workflows. Fragmented data that requires manual reconciliation creates bottlenecks.
Compliance and security: What data protection safeguards are in place? Can they provide documentation for audits? Third-party security attestations (SOC 2 Type II, ISO 27001) indicate mature compliance programs, but you need to verify specific controls relevant to your use cases.
Domain expertise: Do they understand your therapeutic area? Can they provide not just data but strategic interpretation of what patterns mean for your commercial objectives? The gap between having claims data and extracting actionable intelligence is substantial.
Cost structure: Licensing models vary widely—annual subscriptions, per-query fees, project-based arrangements. Total cost of ownership includes not just licensing but also internal resources needed to extract value from the data. A “cheaper” option that requires six months of data engineering may not be cheaper at all.
The challenge many pharmaceutical and MedTech companies face isn’t finding data providers—it’s determining which combination of capabilities, coverage, and cost structures aligns with their strategic priorities. This requires understanding both the vendor landscape and your own organizational needs with precision.
Building Internal Capabilities vs. Outsourcing
A fundamental strategic question for pharmaceutical and MedTech companies is whether to build internal claims analytics capabilities or rely on external partners. There’s no single right answer—it depends on your company’s size, strategic priorities, and existing data science maturity.
Large pharma and MedTech companies often justify building internal capabilities because claims analysis supports multiple business functions—commercial planning, HEOR, medical affairs, regulatory, and business development. The fixed costs of hiring experienced analysts, licensing comprehensive data, and building analytical infrastructure can be amortized across many projects. Internal teams also develop deep understanding of company-specific data assets and can integrate claims insights with proprietary information that external vendors can’t access.
Mid-sized companies frequently adopt hybrid models—licensing claims data and analytics platforms from vendors while maintaining internal expertise to drive strategic questions, interpret findings, and integrate with other business processes. This approach balances capability with cost efficiency.
Emerging biotechs typically outsource claims analytics to specialized partners during development and early commercialization. The sporadic nature of their needs (pre-launch market assessment, post-launch performance tracking at specific milestones) makes fixed internal costs hard to justify. As products mature and portfolios expand, many eventually build limited internal capabilities.
Regardless of approach, some internal capability is essential. Even if you outsource all analyses, someone internally needs to formulate the right questions, evaluate vendor recommendations, and integrate claims insights with strategic planning. This requires professionals who understand both pharmaceutical commercialization and the possibilities and limitations of claims data—a relatively rare combination of expertise.
The Future: Synthetic Data and Emerging Technologies
The frontier of claims data analytics is moving toward synthetic data generation, federated learning, and privacy-preserving computation methods that promise to expand what’s possible while maintaining stringent privacy standards.
Synthetic data involves using machine learning to generate artificial patient records that maintain statistical properties of real claims data but contain no actual patient information. Generative adversarial networks (GANs) and differential privacy techniques can create synthetic datasets that enable scenario modeling, algorithm development, and exploratory analysis without privacy concerns under GDPR or other data protection frameworks.
The commercial applications are compelling. A pharmaceutical company could generate synthetic patient journeys representing various market scenarios—accelerated competitive entry, changing treatment guidelines, new diagnostic capabilities—and test commercial strategies against those scenarios before they occur. MedTech companies could model how procedure volumes might shift under different reimbursement policies.
Federated analytics allows queries to run across multiple distributed datasets without actually moving or centralizing patient-level data. This addresses one of claims data’s persistent limitations: no single database contains everything. Federated approaches could enable analyses across multiple payer systems, integrated delivery networks, and specialized registries while leaving data in place at its source.
Natural language processing applied to unstructured claims notes, prior authorization documents, and clinical narratives will extract information that administrative codes miss. As these capabilities mature, claims data will become richer in clinical detail without requiring linkage to entirely separate data sources.
Real-time analytics platforms are shrinking the lag between when healthcare occurs and when claims-based intelligence becomes available. Traditional closed claims analysis worked with data that might be 6-12 months old by the time it was analyzed. Emerging platforms process open claims within days of the encounter, enabling near real-time competitive intelligence and market monitoring.
Practical Recommendations for Getting Started
If you’re a pharmaceutical or MedTech leader evaluating how to leverage claims data more effectively for market research, these recommendations can accelerate your progress:
Start with specific business questions, not data exploration. “We have access to claims data, what can we learn?” is the wrong framing. Better: “We need to size the second-line NSCLC market, understand switching patterns from first-line therapy, and identify high-volume medical oncologists in our top 50 territories.” Specific questions drive appropriate data source selection and analytical approaches.
Invest in talent with dual expertise. The most valuable team members combine pharmaceutical industry knowledge with real-world data analytics capabilities. Epidemiologists who understand drug development, data scientists who’ve supported commercial teams, HEOR professionals who’ve worked with claims databases—these profiles are more valuable than pure data scientists or pure pharma marketers alone.
Understand your requirements before evaluating options. Companies often jump to vendor selection before clearly defining what they need. Document your coverage requirements (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration needs (API access, data formats), compliance constraints (GDPR, HIPAA), and budget parameters. This clarity prevents costly mismatches.
Pilot before committing to large-scale initiatives. Start with a focused project in one therapeutic area or geographic market. Use that pilot to validate that claims data can answer your questions, refine your analytical methods, and build organizational buy-in. Scale after proving value, not before.
Integrate claims insights into existing workflows. Claims analytics shouldn’t be a standalone research function that produces quarterly reports no one reads. The insights need to flow into brand planning, medical affairs strategy, field force deployment, and payer negotiations. Design integration from the beginning.
Document methodology rigorously. Whether you’re generating evidence for internal decision-making or external regulatory submissions, document every analytical decision—data source selection, patient definition algorithms, statistical methods, sensitivity analyses. This documentation becomes critical when stakeholders question your conclusions or you need to reproduce analyses months later.
Leverage expert guidance for vendor selection. The claims data landscape is complex, with dozens of providers offering overlapping but distinct capabilities. Understanding which combination of coverage, analytical tools, and domain expertise matches your specific needs requires deep market knowledge. Expert advisors who understand both your business objectives and the vendor landscape can accelerate your path to value while avoiding costly mismatches.
Your Next Steps
Claims data has fundamentally changed pharmaceutical and MedTech market research, moving from abstract prevalence modeling to direct measurement of patient journeys, treatment patterns, and market dynamics. The companies leveraging this capability most effectively are those that combine comprehensive data access, sophisticated analytical methods, and deep domain expertise.
The technical barriers to claims analytics have largely dissolved. Data is available, platforms can process it, and analytical methods are well-established. What remains challenging is asking the right questions, interpreting findings in strategic context, and building organizational capabilities that can sustain sophisticated RWE generation over time.
Whether you’re preparing for product launch, evaluating competitive threats, building payer value propositions, or supporting regulatory submissions, claims data provides intelligence that traditional market research simply cannot match. The question isn’t whether to use it—it’s how to navigate the complex landscape of data providers and identify the right match for your specific strategic priorities.
Understanding what types of claims data exist, what questions they can answer, and what limitations they carry is the first step. The second step—matching your requirements to the right combination of data sources, analytical capabilities, and domain expertise—requires guidance from professionals who understand both the pharmaceutical industry and the evolving real-world evidence ecosystem.
Ready to explore how claims data can transform your market research strategy? Learn about strategic approaches to real-world intelligence or see specific use cases for pharmaceutical market sizing with claims data.
Sources & References
- Dang A. Real-World Evidence: A Primer. Pharmaceut Med. 2023;37(1):25-36.
- U.S. Food and Drug Administration. Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products. Guidance Document, 2024.
- Flynn R, et al. Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. Nature Communications. 2022;13:5124.
- Jaksa A, et al. Availability of comparative real-world evidence research in Medicare patients. J Manag Care Spec Pharm. 2023;29(10):1118-1126.
- Zhu R, et al. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval—An Industry Perspective. Clin Pharmacol Ther. 2023;114(2):396-409.
- Purpura CA, et al. Use of real-world evidence in economic assessments of pharmaceuticals in the United States. J Manag Care Spec Pharm. 2021;27(1):98-108.
- Eichler HG, et al. Use of real-world evidence in translational pharmacology research. Br J Clin Pharmacol. 2022;88(4):1508-1515.
- Franklin JM, et al. When Can We Trust Real-World Data To Evaluate New Medical Treatments? Clin Pharmacol Ther. 2022;111(1):24-33.
- Concato J, et al. Real-world evidence to support regulatory decision making: New or expanded medical product indications. Pharmacoepidemiol Drug Saf. 2021;30(8):1007-1013.
- Berger ML, et al. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design. Clin Pharmacol Ther. 2022;111(3):597-606.
- Kim HS, et al. The bird’s-eye view: A data-driven approach to understanding patient journeys from claims data. Health Serv Res. 2020;55(6):1045-1055.
- Shih YC, et al. Use of Claims Data for Cost and Cost-Effectiveness Research. Semin Radiat Oncol. 2019;29(4):336-345.
Previous Post: Real-World Evidence Healthcare Datasets for Pharma
Next Post: Use Case: Pharma Market Sizing with Real-World Insurance Claims Data
Category: Real World Evidence Strategy & Analytics
